A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy

Sophia K. McKinley, Jennifer T. Huang, Jennifer Tan, Daniela Kroshinsky, Stephen Gellis

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disorder that occurs infrequently in children. Although typically associated with a good prognosis in children, there are rare cases that are refractory to treatment with conventional immunosuppressive therapy. Rituximab, an anti-CD20 monoclonal antibody, has been reported to be effective in the adult form of EBA. We report a case of a child with severe and recalcitrant EBA exhibiting a sustained response to treatment with rituximab.

Original languageEnglish
Pages (from-to)241-244
Number of pages4
JournalPediatric Dermatology
Volume31
Issue number2
DOIs
StatePublished - Mar 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy'. Together they form a unique fingerprint.

Cite this